Antidepressants

Psychiatry

Volumn 6, Issue 7, 2007, Pages 289-294

  Nash, Jon ^a,b   Nutt, David ^a,b  

^a Jon Nash MBChB MRCP MRCPsych is a Specialist Registrar in Learning Disability Psychiatry in Weston s   (United States)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

antidepressant; bupropion; depression; dopamine; MAOI; mirtazapine; monoamine; noradrenaline; serotonin; SNRI; SSRI; TCA

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOSULEPIN; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; ISOCARBOXAZID; LOFEPRAMINE; MAPROTILINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PHENELZINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

AGGRESSION; AGITATION; ANOREXIA; ANTICHOLINERGIC EFFECT; ANXIETY; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; HEADACHE; HUMAN; HYPERREFLEXIA; IRRITABILITY; NAUSEA; ORTHOSTATIC HYPOTENSION; PRESCRIPTION; PRIAPISM; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; SEDATION; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDAL IDEATION; SWEATING; TREMOR; URINARY DYSFUNCTION;

EID: 34347244537     PISSN: 14761793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mppsy.2007.04.005     Document Type: Review

References (16)

1. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58 (2000) 19-36
2. MacGillivray S., Arroll B., Hatcher S., et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. Br Med J 326 (2003) 1014
3. Munoz-Arroyo R., Sutton M., and Morrison J. Exploring potential explanations for the increase in antidepressant prescribing in Scotland using secondary analyses of routine data. Br J Gen Pract 56 (2006) 423-428
4. Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol 13 (2003) 57-66
5. Nutt D.J. The neuropharmacology of serotonin and noradrenaline in depression. Int Clin Psychopharmacol 17 suppl 1 (2002) S1-S12
6. Nutt D.J. Death by tricyclic: the real antidepressant scandal?. J Psychopharmacol 19 (2005) 123-124
7. Gillman P.K. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry 59 (2006) 1046-1051
8. Nutt D.J. Death and dependence: current controversies over the selective serotonin reuptake inhibitors. J Psychopharmacol 17 (2003) 355-364
9. Anderson I.M., Nutt D.J., and Deakin J.F.W. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol 14 (2000) 3-20
10. Shelton C., Entsuah R., Padmanabhan S.K., and Vinall P.E. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. Int Clin Psychopharmacol 20 (2005) 233-238
11. Clayton A.H. Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity?. Expert Opin Pharmacother 8 (2007) 457-466
12. Taylor D., Paton C., and Kerwin R. The 2005-2006 Maudsley prescribing guidelines. 8th edn. (2005), Taylor & Francis, London
13. National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical Guideline 23 (2004), National Collaborating Centre for Mental Health, London
14. Zupancic M., and Guilleminault C. Agomelatine: a preliminary review of a new antidepressant. CNS Drugs 20 (2006) 981-992
15. Amsterdam J.D., and Bodkin J.A. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol 26 (2006) 579-586
16. Rosenzweig-Lipson S., Beyer C.E., Hughes Z.A., et al. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 113 (2007) 134-153